2025 Vol.43, N°7 - Table of contents
July 2025
One year in review
CER18888
2025,43,7
Pg. 1195-1203
Free to view
Osteogenesis imperfecta, diffuse idiopathic skeletal hyperostosis, and hypophosphatasia: one year in review 2025
G. De Mattia, L. Pisapia, C. Sgorbini, M. Mazzantini
DOI: https://doi.org/10.55563/clinexprheumatol/3ol69g
G. De Mattia, L. Pisapia, C. Sgorbini, M. Mazzantini
DOI: https://doi.org/10.55563/clinexprheumatol/3ol69g
Environmental Rheumatology
CER18703
2025,43,7
Pg. 1204-1212
Free to view
Infections preceding diagnosis associated with myositis phenotypes in a national patient registry
T. Ohnishi, J. Wilkerson, N. Bayat, P.N. Farhadi, A. Faiq, C.F. Dillon, A. Schiffenbauer, C.G. Parks, H.I. Brunner, B. Goldberg, F.W. Miller, L.G. Rider
DOI: https://doi.org/10.55563/clinexprheumatol/tjpsdy
T. Ohnishi, J. Wilkerson, N. Bayat, P.N. Farhadi, A. Faiq, C.F. Dillon, A. Schiffenbauer, C.G. Parks, H.I. Brunner, B. Goldberg, F.W. Miller, L.G. Rider
DOI: https://doi.org/10.55563/clinexprheumatol/tjpsdy
Editorial
CER18514
2025,43,7
Pg. 1213-1217
Free to view
The Thumb Rule – an approach to optimise musculoskeletal ultrasound scanning in Rheumatology
E. Filippucci, L. Terslev, S.T. Torp-Pedersen, E. Cipolletta
DOI: https://doi.org/10.55563/clinexprheumatol/dpq2qm
E. Filippucci, L. Terslev, S.T. Torp-Pedersen, E. Cipolletta
DOI: https://doi.org/10.55563/clinexprheumatol/dpq2qm
Full Papers
CER17916
2025,43,7
Pg. 1218-1226
Free to view
Impact of a clinical pharmacist consultation on enhancing knowledge and safety skills in patients with chronic inflammatory arthritis treated with bDMARDs
C. Bottois, C. Lopez Medina, S. Dumas, J. Hubert, S. Belo, C. Roux, O. Conort, M. Dougados
DOI: https://doi.org/10.55563/clinexprheumatol/mhtjub
C. Bottois, C. Lopez Medina, S. Dumas, J. Hubert, S. Belo, C. Roux, O. Conort, M. Dougados
DOI: https://doi.org/10.55563/clinexprheumatol/mhtjub
CER18188
2025,43,7
Pg. 1227-1234
Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS
F. Lam, K.L. Chan, C.H. To, C.C. Mok
DOI: https://doi.org/10.55563/clinexprheumatol/1n8j8d
F. Lam, K.L. Chan, C.H. To, C.C. Mok
DOI: https://doi.org/10.55563/clinexprheumatol/1n8j8d
CER18308
2025,43,7
Pg. 1235-1244
Free to view
Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study
O. Katsouli, P. Orfanos, V. Lainis, P. Katsouli, G. Kapellos, P.G. Vlachoyiannopoulos
DOI: https://doi.org/10.55563/clinexprheumatol/5kr6kk
O. Katsouli, P. Orfanos, V. Lainis, P. Katsouli, G. Kapellos, P.G. Vlachoyiannopoulos
DOI: https://doi.org/10.55563/clinexprheumatol/5kr6kk
CER18325
2025,43,7
Pg. 1245-1251
Expression and significance of NF-κB and HSP90 in renal puncture tissues and peripheral blood mononuclear cells of patients with lupus nephritis
X. Hou, Y. Zhang, W. Yang, G. Zou, Y. Liu
DOI: https://doi.org/10.55563/clinexprheumatol/jzt8sp
X. Hou, Y. Zhang, W. Yang, G. Zou, Y. Liu
DOI: https://doi.org/10.55563/clinexprheumatol/jzt8sp
CER18221
2025,43,7
Pg. 1252-1258
Soluble TREM-1 ameliorates gouty arthritis by selective inhibition of proinflammatory cytokines and chemokines without affecting TGFβ production.
Y. Molad, I. Lagovsky
DOI: https://doi.org/10.55563/clinexprheumatol/jv9d10
Y. Molad, I. Lagovsky
DOI: https://doi.org/10.55563/clinexprheumatol/jv9d10
CER18138
2025,43,7
Pg. 1259-1276
Heterogeneity of peripheral immune cell landscape in systemic lupus erythematosus patients after belimumab treatment
W. Sun, C. Yang, J. Zhang, Z. Qu, X. Hou, N. Liu, J. Yang, J. Sun, L. Wang, H. Wang, Z. Wang, D. Xu
DOI: https://doi.org/10.55563/clinexprheumatol/5i2xln
W. Sun, C. Yang, J. Zhang, Z. Qu, X. Hou, N. Liu, J. Yang, J. Sun, L. Wang, H. Wang, Z. Wang, D. Xu
DOI: https://doi.org/10.55563/clinexprheumatol/5i2xln
CER18452
2025,43,7
Pg. 1277-1284
The co-occurrence of IgG4-related disease and malignancy: insights from a prospective cohort study
Y. Guo, Y. Wang, M. Lu, H. Wang, C. Xue, X. Zheng, W. Zhang, Y. Zhao, J. Zhang, K. Li, J. Zhang, F. Huang, J. Zhu
DOI: https://doi.org/10.55563/clinexprheumatol/5c7nti
Y. Guo, Y. Wang, M. Lu, H. Wang, C. Xue, X. Zheng, W. Zhang, Y. Zhao, J. Zhang, K. Li, J. Zhang, F. Huang, J. Zhu
DOI: https://doi.org/10.55563/clinexprheumatol/5c7nti
CER18480
2025,43,7
Pg. 1285-1293
Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice
F. Oudart, M. Thomas, A. Combier, A. Molto, Y. Allanore, J. Avouac
DOI: https://doi.org/10.55563/clinexprheumatol/7r3hxm
F. Oudart, M. Thomas, A. Combier, A. Molto, Y. Allanore, J. Avouac
DOI: https://doi.org/10.55563/clinexprheumatol/7r3hxm
CER17280
2025,43,7
Pg. 1294-1302
Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study
D. Song, J. Wang, H. Zhou, L. Wu, J. Zhang, Z. Wang
DOI: https://doi.org/10.55563/clinexprheumatol/7l4od4
D. Song, J. Wang, H. Zhou, L. Wu, J. Zhang, Z. Wang
DOI: https://doi.org/10.55563/clinexprheumatol/7l4od4
CER18397
2025,43,7
Pg. 1303-1312
Identification and validation of fibroblast-related biomarkers in rheumatoid arthritis by bulk RNA-seq and single-cell RNA-seq analysis
Y.K. Wu, L. Zhou, G. Chang, R.Q. Wang
DOI: https://doi.org/10.55563/clinexprheumatol/x6am51
Y.K. Wu, L. Zhou, G. Chang, R.Q. Wang
DOI: https://doi.org/10.55563/clinexprheumatol/x6am51
CER18458
2025,43,7
Pg. 1313-1320
Peritenon extensor tendon inflammation at metacarpophalangeal joints level: a valuable ultrasound finding in the differential diagnosis between psoriatic arthritis and rheumatoid arthritis?
T. Okano, M. Di Carlo, F. Salaffi, E. Filippucci
DOI: https://doi.org/10.55563/clinexprheumatol/b90gug
T. Okano, M. Di Carlo, F. Salaffi, E. Filippucci
DOI: https://doi.org/10.55563/clinexprheumatol/b90gug
CER18476
2025,43,7
Pg. 1321-1331
A comprehensive analysis of trends and inequalities in rheumatoid arthritis burden among women of childbearing age: insights from the Global Burden of Disease Study 2021
C. Li, S. Zong
DOI: https://doi.org/10.55563/clinexprheumatol/r9rruc
C. Li, S. Zong
DOI: https://doi.org/10.55563/clinexprheumatol/r9rruc
Reviews
CER17960
2025,43,7
Pg. 1332-1344
Cross-reactivity of anti-modified protein antibodies in rheumatoid arthritis
G. Zhang, L. Yao, Q. Zhu, M. Herrmann, Y. Zhao
DOI: https://doi.org/10.55563/clinexprheumatol/c0eeg7
G. Zhang, L. Yao, Q. Zhu, M. Herrmann, Y. Zhao
DOI: https://doi.org/10.55563/clinexprheumatol/c0eeg7
CER18147
2025,43,7
Pg. 1345-1353
Correlations between IgG4-related disease and allergic reactions: implications for future therapeutic strategies
D. Lian, Q. Hao, Y. Liu
DOI: https://doi.org/10.55563/clinexprheumatol/2g7num
D. Lian, Q. Hao, Y. Liu
DOI: https://doi.org/10.55563/clinexprheumatol/2g7num
Paediatric Rheumatology
CER18306
2025,43,7
Pg. 1354-1362
Effectiveness and safety of bisphosphonates in inflammatory bone disorders: a systematic review
S.M. Al-Mayouf, F. Alenzi, Y. Khamaj, S. Aljazaeri, L. Fouda, A. Alsaleem, R. Alhuthil
DOI: https://doi.org/10.55563/clinexprheumatol/y0ve3b
S.M. Al-Mayouf, F. Alenzi, Y. Khamaj, S. Aljazaeri, L. Fouda, A. Alsaleem, R. Alhuthil
DOI: https://doi.org/10.55563/clinexprheumatol/y0ve3b
Letters to the Editor
CER18159
2025,43,7
Pg. 1363
Free to view
Systemic lupus erythematosus-related macrophage activation syndrome inducing severe cytopenia successfully treated with anifrolumab: a case report
E. Chiara, M. Gasparotto, D. Malandrino, E. Biancalana, M.L. Uban, E. Silvestri, G. Emmi
DOI: https://doi.org/10.55563/clinexprheumatol/uumehz
E. Chiara, M. Gasparotto, D. Malandrino, E. Biancalana, M.L. Uban, E. Silvestri, G. Emmi
DOI: https://doi.org/10.55563/clinexprheumatol/uumehz
CER18377
2025,43,7
Pg. 1364
Free to view
Efficacy of anifrolumab as a first-line therapy for the treatment of thrombocytopenia in systemic lupus erythematosus: a case report
F. Bottazzi, E. Manna, V. Codullo, G. Zanframundo, C. Montecuccco, L. Cavagna
DOI: https://doi.org/10.55563/clinexprheumatol/s66b34
F. Bottazzi, E. Manna, V. Codullo, G. Zanframundo, C. Montecuccco, L. Cavagna
DOI: https://doi.org/10.55563/clinexprheumatol/s66b34
CER18448
2025,43,7
Pg. 1365
Free to view
Anifrolumab in the management of lupus headaches: a case report
P. Martínez Calabuig, J.J. Fragío Gil, R. González Mazarío, L. Salvador Maicas, M.L. Sanmartín Martínez, C. Campos Fernández
DOI: https://doi.org/10.55563/clinexprheumatol/c227y1
P. Martínez Calabuig, J.J. Fragío Gil, R. González Mazarío, L. Salvador Maicas, M.L. Sanmartín Martínez, C. Campos Fernández
DOI: https://doi.org/10.55563/clinexprheumatol/c227y1
CER18495
2025,43,7
Pg. 1366
Free to view
Persistence of ixekizumab in psoriatic arthritis and the influence of gender
E.C. Cervantes Pérez, D. Dios-Santos, C. Iñiguez, M. Caeiro Aguado, C. García Porrúa, J.A. Pinto Tasende
DOI: https://doi.org/10.55563/clinexprheumatol/re9si5
E.C. Cervantes Pérez, D. Dios-Santos, C. Iñiguez, M. Caeiro Aguado, C. García Porrúa, J.A. Pinto Tasende
DOI: https://doi.org/10.55563/clinexprheumatol/re9si5
CER18526
2025,43,7
Pg. 1367
Free to view
Comment on: The great challenge: bone fragility and environment
G.M. Weisz
DOI: https://doi.org/10.55563/clinexprheumatol/zufilb
G.M. Weisz
DOI: https://doi.org/10.55563/clinexprheumatol/zufilb
CER18587
2025,43,7
Pg. 1368
Free to view
Reply to the comment on: The great challenge: bone fragility and environment
G. De Mattia, M. Mazzantini
DOI: https://doi.org/10.55563/clinexprheumatol/fikslq
G. De Mattia, M. Mazzantini
DOI: https://doi.org/10.55563/clinexprheumatol/fikslq